ID   RB355
AC   CVCL_S611
SY   RB 355; RB-355
DR   cancercelllines; CVCL_S611
DR   Wikidata; Q54949306
RX   PubMed=1679230;
RX   PubMed=1682862;
RX   PubMed=2090524;
RX   PubMed=2365495;
RX   PubMed=2751270;
RX   PubMed=2917337;
RX   PubMed=4018796;
RX   PubMed=23498719;
RX   PubMed=25326674;
RX   PubMed=29192327;
RX   PubMed=30584916;
CC   Problematic cell line: Contaminated. Shown to be a Y-79 derivative (PubMed=1679230). Originally thought to originate from a male patient with retinoblastoma.
CC   Population: Caucasian.
CC   Doubling time: 81.4 +- 5.7 hours (PubMed=2751270); 66 hours (PubMed=25326674).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; Ex2-6del; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; IVS20+1G>A; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Eye, globe; UBERON=UBERON_0010230.
DI   NCIt; C7541; Retinoblastoma
DI   ORDO; Orphanet_790; Retinoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1893 ! Y-79
SX   Female
AG   2Y6M
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 19
//
RX   PubMed=1679230; DOI=10.3109/13816819109023085;
RA   Madreperla S.A., Bookstein R., Jones O.W., Lee W.-H.;
RT   "Retinoblastoma cell lines Y79, RB355 and WERI-Rb27 are genetically
RT   related.";
RL   Ophthalmic Paediatr. Genet. 12:49-56(1991).
//
RX   PubMed=1682862; DOI=10.1016/S0161-6420(91)32134-1;
RA   Chan H.S.L., Thorner P.S., Haddad G., Gallie B.L.;
RT   "Multidrug-resistant phenotype in retinoblastoma correlates with
RT   P-glycoprotein expression.";
RL   Ophthalmology 98:1425-1431(1991).
//
RX   PubMed=2090524; DOI=10.1111/j.1432-0436.1990.tb00479.x;
RA   Griegel S., Heise K., Kindler-Rohrborn A., Rajewsky M.F.;
RT   "In vitro differentiation of human retinoblastoma cells into neuronal
RT   phenotypes.";
RL   Differentiation 45:250-257(1990).
//
RX   PubMed=2365495; DOI=10.1002/ijc.2910460123;
RA   Griegel S., Hong C., Frotschl R., Hulser D.F., Greger V.,
RA   Horsthemke B., Rajewsky M.F.;
RT   "Newly established human retinoblastoma cell lines exhibit an
RT   'immortalized' but not an invasive phenotype in vitro.";
RL   Int. J. Cancer 46:125-132(1990).
//
RX   PubMed=2751270;
RA   Chan H.S.L., Canton M.D., Gallie B.L.;
RT   "Chemosensitivity and multidrug resistance to antineoplastic drugs in
RT   retinoblastoma cell lines.";
RL   Anticancer Res. 9:469-474(1989).
//
RX   PubMed=2917337; DOI=10.1016/0165-4608(89)90079-4;
RA   Horsthemke B., Greger V., Becher R., Passarge E.;
RT   "Mechanism of i(6p) formation in retinoblastoma tumor cells.";
RL   Cancer Genet. Cytogenet. 37:95-102(1989).
//
RX   PubMed=4018796; DOI=10.1007/BF00295364;
RA   Squire J.A., Gallie B.L., Phillips R.A.;
RT   "A detailed analysis of chromosomal changes in heritable and
RT   non-heritable retinoblastoma.";
RL   Hum. Genet. 70:291-301(1985).
//
RX   PubMed=23498719; DOI=10.1016/S1470-2045(13)70045-7;
RA   Rushlow D.E., Mol B.M., Kennett J.Y., Yee S., Pajovic S.,
RA   Theriault B.L., Prigoda-Lee N.L., Spencer C., Dimaras H., Corson T.W.,
RA   Pang R., Massey C., Godbout R., Jiang Z., Zacksenhaus E., Paton K.,
RA   Moll A.C., Houdayer C., Raizis A., Halliday W., Lam W.L.,
RA   Boutros P.C., Lohmann D.R., Dorsman J.C., Gallie B.L.;
RT   "Characterisation of retinoblastomas without RB1 mutations: genomic,
RT   gene expression, and clinical studies.";
RL   Lancet Oncol. 14:327-334(2013).
//
RX   PubMed=25326674; DOI=10.1007/s00418-014-1285-z;
RA   Busch M., Philippeit C., Weise A., Dunker N.;
RT   "Re-characterization of established human retinoblastoma cell lines.";
RL   Histochem. Cell Biol. 143:325-338(2015).
//
RX   PubMed=29192327; DOI=10.3892/or.2017.6100;
RA   Busch M.A., Papior D., Stephan H., Dunker N.;
RT   "Characterization of etoposide- and cisplatin-chemoresistant
RT   retinoblastoma cell lines.";
RL   Oncol. Rep. 39:160-172(2018).
//
RX   PubMed=30584916; DOI=10.1016/j.yexcr.2018.12.018;
RA   Schwermer M., Hiber M., Dreesmann S., Rieb A., Theissen J., Herold T.,
RA   Schramm A., Temming P., Steenpass L.;
RT   "Comprehensive characterization of RB1 mutant and MYCN amplified
RT   retinoblastoma cell lines.";
RL   Exp. Cell Res. 375:92-99(2019).
//